Biomed & Biotech Firms - Publicly Traded*

(LGND) $790,579,834 Research, milestone and royalty revenue activities resulting from its collaborations with pharmaceutical partners
(HALO) $932,445,740 Research focuses on human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits
(VICL) $285,279,022 Research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases
(SQNM) $506,665,405 Provides products, services, diagnostic testing, applications and genetic analysis products that translate the results into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research
(ADMP) $71,011,032 Operates as a biopharmaceutical company combining specialty pharmaceuticals and biotechnology products to provide medicines for patients, physicians and health care organizations
(LIFE) $12,744,035,156 Molecular biology-based technologies;; cell culture media and sera, stem cells and related tools, cellular imaging products, antibodies, drug discovery services, and cell therapy related products used in the study of cell function;; capillary electrophoresis systems and reagents, and next generation sequencing systems and reagents, as well as reagent kits
(LFVN) $280,972,015 Identification, research, development, manufacture and distribution of nutraceutical dietary supplements in the United States
(LPTN) $61,177,643 Focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating human diseases primarily in the United States
(BMSN) $5,595,237 Focuses on the development of regenerative medicine therapies and tools
(LJPC) $2,286,467 Focuses on the development of a novel class of compounds known as Regenerative Immunophilin Ligands (RILs) in the field of regenerative medicine
(ACAD) $1,590,568,237 Focuses on drug discovery and clinical development of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders
(ANX) - Focuses on developing proprietary product candidates
(AEMD) $17,648,796 Focuses on creating devices for the treatment of cancer and infectious diseases
(SRNE) $100,822,624 Focuses on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of various disease conditions, such as cancer, inflammation, metabolic and infectious diseases in the United State
(CADX) $590,315,430 Focuses on acquiring, in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada
(APRI) $84,047,623 Engages in the research and development of pharmaceutical drugs and drug candidates based on its proprietary NexACT drug delivery technology
(SOMX) - Engages in the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology
(ENTB) - Engages in the development and commercialization of immunotherapeutic therapies for the veterinary market
(MNOV) - Engages in the acquisition and development of small-molecule therapeutics for the treatment of serious diseases for the United States market
(SNTS) $1,392,778,320 Engages in acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists
(PURE) $4,459,022 Discovery, development, and commercialization of bioscience products principally in the United States
(INO) - Discovery, development and delivery of DNA vaccines with a focus on cancers and infectious diseases
(NBIX) $907,560,242 Discovery, development and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders
(AMLN) - Discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases
(TSRX) $402,604,553 Discovery, development and commercialization of antibiotics for life-threatening infections
(SNMX) $85,725,769 Discovery and development of novel flavor ingredients in the savory, sweet, salt, bitter and cooling areas using proprietary taste receptor-based assays and screening technologies
(ISIS) $3,231,248,047 Discovery and development of antisense drugs
(ARNA) $1,626,794,678 Discovering, developing and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory and metabolic diseases
(ILMN) $9,299,908,203 Develops, manufactures and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa
(QDEL) $886,116,455 Develops, manufactures and markets diagnostic testing solutions for applications in infectious diseases, women’s health and gastrointestinal diseases
(IAGXQ) $1,653,580 Develops, formulates, and markets over-the-counter nutritional supplements and skincare products
(CYTX) $156,536,499 Develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects
(SCIE) $8,121,910 Develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy
(TEAR) $324,482,727 Develops and commercializes TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease
(GPRO) - Development, manufacture and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood
(RMD) $6,432,331,543 Development, manufacture and distribution of medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders
(OREX) $561,227,783 Development of pharmaceutical product candidates for the treatment of obesity
(DRAD) - Development and manufacture of medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications primarily in the United States
(OPTR) $709,374,878 Development and commercialization of pharmaceutical products
(ATEC) $199,167,328 Designs, develops, manufactures and markets products for the surgical treatment of spine disorders
(VOLC) $990,723,755 Designs, develops, manufactures and commercializes intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products used in the diagnosis and treatment of vascular and structural heart disease
(DXCM) $1,596,750,610 Design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes
(NUVA) $1,117,245,728 Design, development and marketing of minimally disruptive surgical products and procedures for the spine
(CFN) $8,183,496,582 Critical care technologies, medical technologies and services
(CXM) $9,652,374 Acquires and develops product opportunities and businesses, focusing on the development and commercialization of novel therapeutics and medical devices for cardiovascular and ischemic diseases, wound healing, and tissue repair
(ANDS) - -
(RDEA) - -
(CYPB) - -
(GXDX) - -
(HRBR) $6,482,252 -
(IMMY) $71,017,113 -
(ISCO) $25,850,119 -
(LANZ) $2,076,615 -
(MSTX) $42,366,360 -
(MEIP) $123,410,477 -
(NGEN) - -
(NAII) $32,086,185 -
(ONCS) $28,618,450 -
(ONVO) $249,691,498 -
(RGLS) $372,855,347 -
(TDLP) - -
(TROV) $115,242,783 -
(BUGS) - -
(VRNM) $28,382,465 -
(ZGNX) $163,309,937 -
Subscribe Today!